Abstracts tagged "pregnancy"

Abstract Number: 1065 • ACR Convergence 2024
A Quality Improvement Project to Improve Contraception Management in Patients with Systemic Lupus Erythematosus on Teratogenic Medications
Marta Bean¹, Brian Coburn¹, Thomas Riley², Elise Breed¹, Carlos M García-González¹, Akash Gupta¹, Jonathan Kotzin¹, Adam Mayer³, John Oghene¹, Ellen Romich⁴, Michael George¹, Rachel Dayno¹, Nora Sandorfi¹, Preethi Thomas¹ and Anupama Shahane¹, ¹University of Pennsylvania, Philadelphia, PA, ²Hopsital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University of Pennsylvania, Media, PA
Background/Purpose: Many patients with systemic lupus erythematosus (SLE) require teratogenic medications for management of their disease. Reliable contraception is important to avoid unintended pregnancy in…
Abstract Number: 0425 • ACR Convergence 2024
Use of bDMARDs During Pregnancy After Preconceptional Counseling in Spanish Patients with Rheumatic Diseases
Antia Garcia Fernandez¹, Fernando Rengifo-Garcia¹, Raquel Senosiain-Echarte¹, Miguel Álvaro Navidad¹, Miguel Angel Gonzalez-Gay² and Juan Antonio Martínez - López¹, ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ²University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain
Background/Purpose: Current recommendations advocate maintaining pregnancy-compatible bDMARDs during pregnancy (mainly TNF inhibitors) and monitoring disease activity before conception to improve disease and pregnancy outcomes. Recently,…
Abstract Number: 0446 • ACR Convergence 2024
Rheum for Improvement: Contraception Counseling and Adherence in Patients with Lupus and Rheumatoid Arthritis on Teratogenic Medications
Kathryn Kompa¹ and Vasileios Kyttaris², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²BIDMC, Boston, MA
Background/Purpose: Methotrexate (MTX) and mycophenolate (MMF) are two common medications for both lupus (SLE) and rheumatoid arthritis (RA). Both medications are contraindicated in pregnancy, necessitating…
Abstract Number: 1147 • ACR Convergence 2024
Evaluation of Adverse Pregnancy Outcomes in Patients with Inflammatory Myopathies and Ro Positivity
Hillary Weisleder¹, Ana Valle², Caroline Rourke³ and Shereen Mahmood⁴, ¹Montefiore Einstein, New York, NY, ²Brigham and Women's Hospital, Boston, MA, ³Montefiore Medical Center, Bronx, NY, ⁴Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Anti-Ro/SSA antibodies are associated with poor prognostic outcomes in patients with autoimmune disease. The presence of these antibodies can also cause adverse pregnancy outcomes…
Abstract Number: 0428 • ACR Convergence 2024
Placental Characteristics in Systemic Lupus Erythematosus Pregnancies Resulting in Small for Gestational Age Infants
Rashmi Dhital¹, Marni Jacobs², Chelsey Smith³ and Mana Parast², ¹UC San Diego, Brentwood, TN, ²UC San Diego, San Diego, CA, ³UC San Diego, LA JOLLA, CA
Background/Purpose: About a quarter of pregnant individuals with systemic lupus erythematosus (SLE) have small for gestational age (SGA) infants. We aim to characterize placental pathology…
Abstract Number: 0447 • ACR Convergence 2024
Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database
Connie Lin¹, Anja Geldhof², Mauricio Ballina³, Hetal Patel⁴ and Hewei Li⁵, ¹Janssen R&D US, Horsham, PA, ²Director Postmarketing Commitments, Leiden, Netherlands, ³Actelion Research & Development, Basel, Switzerland, Gewerbestrasse, Basel-Landschaft, Switzerland, ⁴Pharmaceutical Companies of Johnson & Johnson, Naperville, IL, ⁵Janssen Pharmaceutical, Hopewell Township, NJ
Background/Purpose: Data pertaining to the use of biologics in immunologic diseases are limited on their use during pregnancy. Guselkumab (GUS) is a human IgG1λ mAb…
Abstract Number: 1322 • ACR Convergence 2024
Maternal Antenatal Attachment in Women with Rheumatic Diseases
Maria Corral-Trujillo¹, Rodrigo Alfonso Cerda González², Luis C Berlanga-Muñoz³, Rodrigo Cantú-Barreda⁴, Brayan U Montes-Rodríguez⁵, Anahí Carrazco Chapa⁶, América M Burciaga Garza⁵, Jesus Cardenas-de la Garza¹, Lorena Perez-Barbosa⁷, CASSANDRA SKINNER TAYLOR⁸ and Dionicio Galarza-Delgado⁹, ¹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ²Universidad Autónoma de Nuevo León, Santa Catarina, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterre, Mexico, ⁴Hospital Universitario, Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁶Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ⁷Hospital Universitario, UANL, Monterrey, Mexico, ⁸HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁹UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: The maternal antenatal attachment (MAA) is defined as the emotional bond between a pregnant woman and her unborn child. The quality of this relationship…
Abstract Number: 0473 • ACR Convergence 2023
The Number of Rheumatoid Arthritis Patients Who Give up Pregnancy Due to the Disease Is Decreasing
Ryo Inoue¹, Sakiko Isojima¹, Toshihiro Matsui², Shigeto Tohma³ and Nobuyuki Yajima⁴, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa City, Tokyo, Japan, ²NHO Sagamihara National Hospital, Kanagawa, Japan, ³NHO Tokyo National Hospital, Dallas, TX, ⁴Showa-Universtiy of Medicine, Tokyo, Japan
Background/Purpose: Biologics have been shown not to be a disruption in pregnancy, and the reproductive health care environment surrounding rheumatoid arthritis patients has improved significantly.…
Abstract Number: 1349 • ACR Convergence 2023
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…
Abstract Number: 1968 • ACR Convergence 2023
Pregnancy Outcomes in Idiopathic Inflammatory Myopathies: A Comparison to the General American Population
Ana Valle¹, Melissa Fazzari² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare autoimmune conditions which cause multi-organ inflammation, particularly in the skin, lungs, and muscles. It is known that many…
Abstract Number: 0474 • ACR Convergence 2023
Acute Cardiovascular Events During Pregnancy and Delivery in Patients with Autoimmune Rheumatic Diseases (ARDs): An Analysis of National Inpatient Sample
Karun Shrestha¹, Prakriti Subedi¹, Manoj Ghimire¹, Sajana Poudel², Kalpana Ghimire¹, Sai Keerthi Parvatheneni¹, Mrunalini Dandamudi¹, Laura Pedraza¹, Luisa Brito¹ and Liliya Gandrabur³, ¹Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY, ²Department of Internal Medicine, John H Stroger Jr Hospital of Cook County, Chicago, IL, ³SBH Health System, Forest Hills, NY
Background/Purpose: Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) & vasculitis are autoimmune rheumatic diseases (ARDs) with systemic involvement. Management of women with ARDs during pregnancy…
Abstract Number: 1350 • ACR Convergence 2023
Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record
Noah Forrest¹, Joshua Waytz², April Barnado³, Megan Clowse⁴, Theresa Walunas¹ and Rosalind Ramsey-Goldman⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern Medicine, Chicago, IL, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Duke University, Chapel Hill, NC, ⁵Northwestern University, Chicago, IL
Background/Purpose: SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in…
Abstract Number: 2278 • ACR Convergence 2023
Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
Cristiana Sieiro Santos¹, Paula Pérez García², Jose Ordas Martínez², Clara Moriano², Carolina Álvarez Castro² and Elvira Díez Álvarez², ¹Complejo Asistencial Universitario de León, León, Spain, ²CAULE, León, Spain
Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…
Abstract Number: 0475 • ACR Convergence 2023
Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States
Sabahat Usmani¹, Catherine Lavallee², Maria Antonelli³ and Cuoghi Edens⁴, ¹Weiss Memorial Hospital, Chicago, IL, ²Virginia Tech Carilion School of Medicine, Roanoke, VA, ³MetroHealth System, Cleveland, OH, ⁴University of Chicago, Chicago, IL
Background/Purpose: Endometriosis (ENDO) and Polycystic Ovarian Syndrome (PCOS) are underdiagnosed, often debilitating conditions with unknown etiologies that, like rheumatic diseases, affect reproductive-aged women. Recent studies…
Abstract Number: 1352 • ACR Convergence 2023
Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study
Yanint Raksadawan¹, Aravind Polam¹, Nattanicha Chaisrimaneepan² and Sabahat Usmani¹, ¹Weiss Memorial Hospital, Chicago, IL, ²Texas Tech University Health Sciences, Lubbock, TX
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis which affects women of reproductive age. There is limited information about the effect of TA on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].